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Background: It is unclear whether an ‘obesity survival paradox’ exists for pneumonia. Therefore, we conducted a
meta-analysis to assess the associations between increased body mass index (BMI), pneumonia risk, and mortality risk.
Methods: Cohort studies were identified from the PubMed and Embase databases. Summary relative risks (RRs) with
their corresponding 95% confidence intervals (CIs) were calculated using a random effects model.
Results: Thirteen cohort studies on pneumonia risk (n = 1,536,623), and ten cohort studies on mortality (n = 1,375,482)
were included. Overweight and obese individuals were significantly associated with an increased risk of pneumonia
(RR = 1.33, 95% CI 1.04 to 1.71, P = 0.02, I2 = 87%). In the dose–response analysis, the estimated summary RR of
pneumonia per 5 kg/m2 increase in BMI was 1.04 (95% CI 1.01 to 1.07, P = 0.01, I2 = 84%). Inversely, overweight and
obese subjects were significantly associated with reduced risk of pneumonia mortality (RR = 0.83, 95% CI 0.77 to 0.91,
P < 0.01, I2 = 34%). The estimated summary RR of mortality per 5 kg/m2 increase in BMI was 0.95 (95% CI 0.93 to 0.98,
P < 0.01, I2 = 77%).
Conclusions: This meta-analysis suggests that an ‘obesity survival paradox’ exists for pneumonia. Because this
meta-analysis is based on observational studies, more studies are required to confirm the results.
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The prevalence of obesity has dramatically increased in
the last two decades [1]. The diagnosis of obesity is often
based on body mass index (BMI), calculated as weight in
kilograms divided by height in meters squared (kg/m2).
The ideal BMI is between 18.5 and 24.9. Being overweight
is considered as having a BMI between 25 and 29.9, and
being classified as obese falls into a BMI of 30.0 or greater
[2]. Obesity is associated with an increased risk of car-
diovascular disease and type 2 diabetes [3,4]. However,
an inverse relationship between obesity and mortality
has been described in patients with heart failure, coronary
heart disease, and diabetes [5-7]. This phenomenon is
known as the ‘obesity survival paradox.’
Pneumonia is one of the most common infectious dis-
eases; however, there is uncertainty about the association* Correspondence: lbxwzhao@gmail.com; xiu_qingyu@126.com
†Equal contributors
1Department of Respiratory Medicine, Shanghai Changzheng Hospital,
Second Military Medical University, 415 Fengyang Road, Shanghai 200003,
China
Full list of author information is available at the end of the article
© 2014 Nie et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.between obesity and pneumonia risk or pneumonia mor-
tality [8-28]. For example, Baik et al. [9] suggested that
obesity was directly associated with the development of
community-acquired pneumonia (CAP). However, Phung
et al. [19] did not find that obesity was significantly associ-
ated with pneumonia risk. Takata et al. [24] indicated that
mortality risk was not different between obese pneumonia
patients and normal weight patients. However, other studies
reported that obese subjects with pneumonia had lower
mortality compared to normal weight subjects [26-28].
Thus, whether the ‘obesity survival paradox’ exists in
pneumonia is still unclear.
To date, no meta-analysis has shown whether an ‘obesity
survival paradox’ exists for pneumonia. The aim of this
meta-analysis was to investigate the relationships between
elevated BMI, pneumonia risk, and mortality.Methods
This meta-analysis was performed according to a predeter-
mined protocol described in the following paragraphs,
using standard systematic review techniques, as outlined by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(MOOSE) criteria [29].
Literature search
A literature search was performed (WN and YZ) using
the PubMed search engine, with the database being last
accessed on 15 June 2013. The Embase database was
also searched for relevant studies published up to June
2013. References from relevant articles were manually
checked for further studies. The detailed search strategy
is presented in the Additional file 1.
Study selection
Two reviewers (WN and YZ) independently screened the
abstracts of papers identified by the literature search, re-
trieved potentially relevant studies and determined study
eligibility. Studies were included if: (1) the study design was
a prospective or retrospective cohort study; (2) the expos-
ure of interest was BMI; (3) they reported adjusted relative
risks (RRs), hazard ratios (HRs) or odds ratios (ORs) with
corresponding 95% confidence intervals (CIs), or provided a
RR/HR/OR with corresponding 95% CI per unit increment
in BMI; and (4) the outcome was pneumonia incidence or
mortality. If the same cohort was used in more than one
publication, we included the publication that reported the
results in greater detail or, if similar, the one with the largest
number of cases. Data published only in abstract form were
excluded. Case reports, review articles and commentary ar-
ticles were also excluded. Studies with pediatric participants
or pregnant populations were not included.
Data collection and methodological quality assessment
From each study, two reviewers (WN and YZ) independ-
ently extracted the first author, publication year, study de-
sign, location where the study was performed, number of
cases and cohort size, gender and age of study participants,
follow-up duration, method for assessing height and weight,
ascertainment of pneumonia, type of pneumonia, BMI cat-
egory, adjusted RR/HR/OR and the corresponding 95% CI,
and covariates controlled for multivariable analysis. The
authors of the relevant studies were contacted by Email if
more information was needed.
Two independent reviewers (WN and YZ) completed
the quality assessment. The Newcastle–Ottawa Scale (NOS)
was used to evaluate the methodological quality, which
scored studies by the selection of the study groups, the
comparability of the groups and the ascertainment of the
outcome of interest [30]. Discrepancies were resolved by
consensus and discussion. The detailed criteria of the meth-
odological quality assessment are in Additional file 2.
Statistical analysis
For pneumonia risk and pneumonia mortality risk, we
calculated summary RRs and 95% CIs for overweightand obesity versus normal weight. The random effects
model was utilized. HRs and ORs were regarded as
equivalent to RRs in cohort studies. If a study reported
results specifically for men and women, respectively, we
combined the sex-specific RR estimates using a fixed-
effects model before combining with other studies.
In dose–response analysis, we calculated the RR per
5-unit increase in the BMI levels for each study. The
average of the natural logarithm of the RRs was estimated
and the RR from each study was weighted by the inverse
of its variance. A two-tailed P < 0.05 was considered statis-
tically significant. We also combined the sex-specific esti-
mates using a fixed-effects model to generate an estimate
for both genders combined. The method described by
Greenland and Longnecker [31] was used for the dose–
response analysis and study-specific slopes (linear trends)
and 95% CIs were computed from the natural logs of the
RRs and CIs across categories of BMI. This method re-
quires the distribution of case and person-years and the
median level of BMI in each category to the corresponding
RR for each study (the RRs with estimates for at least three
quantitative exposure categories are known). The midpoint
between the upper and lower boundary for each BMI
category was assigned to the corresponding RR esti-
mate. For studies with an open-ended highest or lowest
BMI category, we assumed that the amplitude was the
same as the closest adjacent category. Random effects
models were used to pool the respective results. The
dose–response results in the forest plot were presented
for a 5 kg/m2 BMI increment.
Nonlinear dose–response curves were plotted using
restricted cubic splines for each study, using knots
fixed at percentiles 10%, 50% and 90% through the dis-
tribution; then these were combined using multivariate
meta-analysis [32-34].
Statistical heterogeneity among studies was evaluated
using the Q and I2 statistics. For the I2 metric, we con-
sidered low, moderate and high I2 values to be 25%, 50%
and 75%, respectively. We examined the role of several
potential sources of heterogeneity by subgroup analyses
according to study design, gender, ascertainment of case,
pneumonia type, assessment of anthropometry, and dur-
ation of follow-up. Meta-regression was also performed
to find the sources of heterogeneity. Sensitivity analysis
was conducted by excluding one study at a time to explore
whether the results were driven by one large study or
by a study with an extreme result. Potential small study
effects, such as publication bias, were investigated with
funnel plots.
All statistical analyses were performed with the Stata
software (version 12.0, Stata Corporation, College Station,
Texas). A threshold of P < 0.1 was used to decide whether
heterogeneity was present. In other cases, P values were
two sided with a significance level of 0.05.
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Literature search
The process of identifying relevant studies is shown in
Figure 1. The initial search produced 1,035 studies from
the PubMed and Embase databases. After exclusion of
duplicates and irrelevant studies, 115 potentially eligible
studies were selected. After detailed evaluations, 21 studies
were selected for final meta-analysis [8-28]. A manual
search of reference lists from these studies did not yield any
new eligible study. Several studies investigated the associ-
ation between BMI and mortality. We contacted these
authors to get additional data on pneumonia mortality. Dr.
Sun Ha Jee and colleague shared their data [35]. Finally, 22
studies were included in this meta-analysis [8-28,35].
Study characteristics
Twelve cohort studies (n = 1,536,623) investigated the
association between BMI and pneumonia risk [8-19], and
ten studies (n = 1,375,482) assessed the association between
BMI and pneumonia mortality [20-28,35]. There were
seven retrospective cohort studies [11,15-18,25,26] and fif-
teen prospective cohort studies [8-10,12-14,19-24,27,28,35].
The durations of follow-up varied from 1 year to
15.8 years. Sixteen studies collected measured BMI
[8,10-15,19,20,23-28,35]; three studies collected self-reportedFigure 1 Flow of study identification, inclusion and exclusion.data [9,17,21]. The characteristics of each study are
presented in Table 1. The methodological quality as-
sessment is provided in Additional file 2. The Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) checklist for meta-analysis is provided in
Additional file 3.
Quantitative data synthesis
Pneumonia risk (overweight and obesity versus normal weight)
Compared with normal weight individuals, overweight
and obese individuals were associated with a significantly
increased risk of pneumonia (RR = 1.33, 95% CI 1.04 to
1.71, P = 0.02, I2 = 87%). A small-study effect was demon-
strated using a funnel plot [see Additional file 4]. Ten stud-
ies reported RRs for categorized BMI levels [9-17,19]. Thus,
we included these studies for the dose–response analysis.
The summary RR was 1.04 (95% CI 1.01 to 1.07, P = 0.01,
I2= 84%; Figure 2). A potentially nonlinear dose–response
relationship was not detected (P > 0.05; Figure 3). We found
evidence of a small-study effect as assessed by funnel plot
[see Additional file 5].
We conducted a sensitivity analysis by omitting one
study at a time and calculating the pooled RRs for the
remainder of the studies. This sensitivity analysis showed
that the results were not changed (data not shown). The
Table 1 Characteristics of included cohort studies
Author Study
design
Year Location Gender Age (y) Years of
follow-up
(y)
Assessment
of weight
and height
Sample
size
Cases
ascertainment
No. of
cases
Type BMI category
(kg/m2)
Adjustment for covariates
Incidence
Delgado-
Rodriguez
PC 1997 Spain Mixed 53 2 Measured 1,483 Physician-
diagnosed
19 HAP <33.75, ≥33.75 Mechanical ventilation, upper
abdominal surgery, COPD, NNIS index
Baik PC 2000 USA Mixed 56.3 (men)
36.4
(women)
6 Self-reported 104,491 Physician-
diagnosed
595 CAP <21, 21–22.9,
23–24.9, 25–26.9,
27–29.9, ≥30
Age, smoking status, physical activity,
alcohol intake
Newell PC 2007 USA Mixed 45 5 Measured 1,543 NA 315 HAP 18.5–24.9, 25.0–29.9,
30.0–39.9, ≥40
Age, gender, injury severity score,
revised trauma score
Yap RC 2007 Australia Mixed 66.4 6 Measured 3,968 Physician-
diagnosed
174 HAP <20, 20–30, 30–40, ≥40 Age, gender, diabetes,
hypercholesterolemia, renal
impairment, preoperative dialysis,
hypertension, cerebrovascular disease,
peripheral vascular disease, lung disease,
NYHA class IV, severe LV impairment,
mean PA pressure, emergency status
and total bypass time
Dossett PC 2008 USA Mixed 45 NA Measured 1,406 Physician-
diagnosed
446 HAP <18.5, 18.5–24.9,
25.0–29.9, 30.
0–39.9, ≥40
Age, gender, TRISS, AIS head score
Mannino PC 2008 USA Mixed >45 3 Measured 20,375 ICD-9 codes
480-486
214 CAP <20, 20–24, 25–29, ≥30 Age, gender, race, smoking status,
education level, diabetes status,
cardiovascular disease status
Kornum PC 2010 Denmark Mixed 50-64 11.8 Measured 48,551 ICD-10 codes
J12.x–J18.x,
ICD-10codes
A709.x, ICD-10
codes A481.x
2,112 CAP <22.5, 22.5–24.9,
25.0–29.9,30.0–34.9, ≥35
Age, smoking status, alcohol intake,
schooling, educational level
Morgan RC 2010 USA Mixed >20 1 Measured 196,684 Physician-
diagnosed
134 CAP <18.5, 18.5–24.9,
25.0–29.9, 30-39.9, ≥40
Age, gender, chronic disease
Blumentals RC 2011 UK Mixed >18 7 NA 1,074,315 NA 877 CAP <18.5, 18.5–24.9,
25.0–29.9, ≥30
Age, gender, type 2 diabetes,
hypertension, statin use, antibiotic
use, cigarette smoking status,
influenza vaccination status, and
year of index date
Kwong RC 2011 Canada Mixed >18 12 Self-reported 82,545 ICD-9 codes
480–486,
ICD-10-CM
codes J10-J18
228 CAP <18.5, 18.5–24.9,
25.0–29.9, ≥30
Age, gender, influenza vaccination
status, rural residence, income
quintile, smoking status, previous
hospitalizations, previous outpatient
visits, and the presence of chronic
disease
Viasus RC 2011 Spain Mixed 39 NA NA 585 Physician-
diagnosed
11 CAP <30, 30–39.9, ≥40 Age, gender, smoking, alcohol drinking,
comorbid condition, influenza vaccine,
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Table 1 Characteristics of included cohort studies (Continued)
early antiviral treatment, concomitant
and/or secondary bacterial co-infection
Phung PC 2013 Australia Mixed 33 15.6 Measured 677 ICD-9 codes
480–486,
ICD-10
codes J12-J18
141 CAP <18.5, 18.5–24.9,
25.0–29.9, ≥30
Age, smoking, alcohol consumption
status
Mortality
LaCROIX PC 1989 USA Mixed 65.8 12 Measured 5474 ICD-9 codes
480-486
76 CAP Lowest quartile, Second
quartile,Third quartile,
Highest quartile
Age
Salive PC 1993 USA Mixed 74 6 Self-reported 10,269 ICD-9 codes
480-486
403 CAP Lowest quartile, Second
quartile,Third quartile,
Highest quartile
Age, race, education, co-morbidities,
smoking, peak expiratory flow,
emphysema, exercise
Lange PC 1995 Denmark Mixed 30-70 12 NA 13,423 ICD-8 codes
480-486
260 CAP <20, 20–29, ≥30 Age, predicted forced expiratory
volume in one second
Jee PC 2006 Korea Mixed 46 15 Measured 1,213,829 ICD-10 962 CAP <18.5, 18.5–19.9,
20.0–21.4, 21.5–22.9,
23.0–24.9, 25.0–26.4,
26.5–27.9, 28.0–29.9,
30.0–31.9
Age, smoking status, alcohol intake,
physical exercise, physical activity
Inoue PC 2007 Japan Mixed 57.6 13 Measured 110,792 ICD-9 codes
480-486 ICD-10
codes J12-J18
1,082 CAP 10.0–17.9, 18.0–22.9,
23.0–24.9,25.0–32.9
Age, diabetes mellitus
Takata PC 2007 Japan Mixed 80 4 Measured 697 ICD-10 19 CAP <18.5, 18.5–24.9, ≥25 Gender, tobacco use, alcohol use,
weight loss, current outpatient, systolic
blood pressure, physical activity,
functional status, marital status, and
levels of total serum cholesterol
and glucose
Corrales-
Medina
RC 2011 USA Mixed 65.5 7 Measured 266 Physician-
diagnosed
31 CAP <18.5, 18.5–24.9,
25.0–29.9, >30
Age, race, cancer, CURB-65
King RC 2012 USA Mixed 67.5 7 Measured 18,746 ICD-9 codes
480-487
3,340 CAP <18.5, 18.5–24.9,
25.0–29.9, 30-39.9, >40
Age, gender, marital status, race, count
of current medications, medical and
psychiatric comorbid conditions, alcohol
abuse, tobacco use, and drug abuse
Kahlon PC 2012 Canada Mixed 68 2 Measured 907 Physician-
diagnosed
79 CAP <18.5, 18.5–24.9,
25.0–29.9, >30
Age, functional status, prior
pneumococcal vaccination, chest
radiograph confirmation, PSI
Singanayagam PC 2013 UK Mixed 50-78 NA Measured 1,079 Physician-
diagnosed
103 CAP <18.5, 18.5–24.9,
25.0–29.9,30.0–34.9
Age, gender, co-morbidities, current
smoking, functional status, nursing
home residence, PSI
AIS, abbreviated injury score; BMI, body mass index; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary diseases, CURB-65, confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/minute,
low blood pressure and age ≥65 years; F, female; HAP, hospital-acquired pneumonia; ICD, International Classification of Diseases; LV, left ventricle; M, male; NA, not available; NNIS, National Nosocomial Infection
Surveillance; NYHA, New York Heart Association; PC, prospective cohort; PSI, Pneumonia Severity Index; RC, retrospective cohort; TRISS, trauma-related injury severity score.
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Figure 2 Relative risks of pneumonia risk per 5 kg/m2 increase in body mass index. CI: indicates confidence interval; and RR: risk ratio.
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stratifying analyses. Studies comparing overweight and
obese subjects with normal weight subjects, and studies
assessing dose–response associations were explored,
respectively. The positive relationship between BMI
and risk of pneumonia was significant in subgroups by
ascertainment of case and assessment of weight and height
[see Additional file 6]. However, in subgroups of retro-
spective cohort studies, male population, female popula-
tion, hospital-acquired pneumonia, and longer follow-up
duration, the positive relationships were not statistically
significant [see Additional file 6]. A meta-regression found
that assessment of weight and height might be the source
of the high heterogeneity.Figure 3 Dose–response relationship between body mass index
and relative risk of pneumonia. Body mass index was modeled
with a nonlinear trend (black continuous line) in a random effects
meta-regression model. Long-dashed black lines represent 95%
confidence intervals. Short-dashed black lines represent the linear
trend. The vertical axes are on a log scale.Pneumonia mortality risk (overweight and obese versus
normal weight)
Overweight and obese individuals were associated with
decreased mortality risk (RR = 0.83, 95% CI 0.77 to 0.91,
P < 0.01, I2 = 34%). A small-study effect was revealed by
the funnel plot [see Additional file 7].
Six cohort studies were identified in the dose–response
analysis [23,25-28,35]. The summary RR was 0.95 (95% CI
0.93 to 0.98, P < 0.01, I2 = 77%; Figure 4). There was no
evidence of a nonlinear relationship with BMI (P = 0.44;
Figure 5). The shape of the funnel plot was asymmet-
rical, suggesting that there was a small-study effect
[see Additional file 8].
In sensitivity analyses, no result was significantly altered
when excluding studies one by one (data not shown).
Stratified analyses were defined by study design, gender,
assessment of weight and height, and follow-up duration.
Studies comparing overweight and obese subjects with
normal weight subjects, and studies assessing dose–response
associations were explored, respectively. The inverse rela-
tionship between BMI and risk of mortality was significant
in subgroups that were defined by ascertainment of case
and study design. However, in the female subgroup or stud-
ies with shorter follow-up duration, the inverse relationship
was not statistically significant [see Additional file 9]. Study
design was found to be the major source of heterogeneity
by meta-regression.
Discussion
In this meta-analysis, we showed that an ‘obesity survival
paradox’ might exist for pneumonia. On the one hand,
there was a positive association of obesity with pneumonia
Figure 4 Relative risks of pneumonia mortality risk per 5 kg/m2increase in body mass index. CI: indicates confidence interval; and RR:
risk ratio.
Nie et al. BMC Medicine 2014, 12:61 Page 7 of 9
http://www.biomedcentral.com/1741-7015/12/61risk. On the other hand, pneumonia mortality was lower
for patients with high BMI compared to normal BMI.
In a recent meta-analysis, Phung and coworkers found
a J-shaped relationship between BMI and risk of CAP
and a U-shaped relationship between BMI and risk of
influenza-related pneumonia [36]. Our results were partly
similar to this previous report. In the current meta-analysis,
we only investigated the association between higher BMI
and pneumonia risk, but did not assess the association
between subnormal BMI and pneumonia risk. Thus, the
shape of our dose–response relationship deviated from
J-shaped or U-shaped.
There were several potential explanations for why obese
individuals may have higher risk of pneumonia. First,
obesity is often accompanied by co-morbid conditions,
such as gastroesophageal reflux disease [37]. When refluxFigure 5 Dose–response relationship between body mass index
and relative risk of pneumonia mortality. Body mass index was
modeled with a nonlinear trend (black continuous line) in a random
effects meta-regression model. Long-dashed black lines represent
95% confidence intervals. Short-dashed black lines represent the
linear trend. The vertical axes are on a log scale.of gastric fluid occurs, the fluid can be aspirated into the
respiratory tract resulting in pneumonia [37]. Second, obes-
ity has been shown to be an independent predictor of
diabetes and asthma. These two diseases are also important
risk factors for pneumonia [38,39]. Third, a recent study
reported that a higher BMI led to lower 25(OH)D3 levels
[40]. More recently, Aregbesola and colleagues found that
subjects with a lower serum 25(OH)D3 concentration had a
higher risk of pneumonia [41]. Fourth, leptin (ob/ob) and
leptin receptor (db/db) deficient mice showed severe im-
mune abnormalities and greater susceptibility to viral and
bacterial infection [42]. Individuals with this leptin defect
also exhibited greater susceptibility to respiratory infections
[43]. Therefore, leptin plays an important role in the human
immune response to infectious disease. Although there
were elevated leptin levels in obese subjects, leptin re-
sistance often coexisted with these persons [44]. Taken
together, these results suggest that individuals with high
BMI might have an increased risk of pneumonia compared
to subjects with normal BMI.
This present meta-analysis suggested a survival advantage
for obese patients with pneumonia. A study by LaCroix
et al. showed that the risk of pneumonia mortality was 2.6
times higher in men of the lowest BMI quartile compared
to the highest quartile [20]. Another study by Salive et al.
indicated that the highest two quartiles of BMI had a sig-
nificantly reduced risk of mortality compared with the low-
est quartile [21]. We propose three explanations for the
inverse relationship between obesity and the risk of pneu-
monia mortality. First, obese individuals have a higher risk
of developing coronary heart disease, type II diabetes, and
heart failure [45]. Thus, obese patients with pneumonia
may receive optimal medical treatment or aggressive treat-
ment. This may lead to a reduction in mortality. Second,
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flammatory cytokine that plays a critical role in inflamma-
tory and immune responses. Puren et al. [46] indicated
that the plasma level of TNF-α is a marker of pneumonia
severity. Adipose tissue is known to produce soluble TNF-
α receptors [47]. Additionally, recent studies showed that
obese patients with pneumonia had lower pneumonia se-
verity index scores and plasma levels of C-reactive protein
[27,28]. Third, as with other diseases, patients with pneu-
monia who are at a normal weight may not have enough
metabolic reserve to counteract the increased catabolic
stress. These patients may be particularly vulnerable to
the adverse pathophysiologic consequences of a limited
metabolic reserve.
There are several limitations of the current study. First, a
meta-analysis of observational studies inherits the limita-
tion of the original studies. Although most studies adjusted
for potential confounders, such as age, gender, smoking
and underlying diseases, the possibility of residual con-
founding cannot be ruled out. Because this meta-analysis
investigated only BMI, we cannot exclude the possibility
that the observed associations may be confounded by other
lifestyle factors, such as lower physical activity or diet-
ary factors. Second, the number of available studies
that were included in this meta-analysis was moderate.
Therefore, the results could be influenced by some factors,
such as random error. Third, most of the studies used
International Classification of Diseases (ICD)-9 or ICD-10
codes to classify pneumonia. van de Garde and coworkers
suggested that ICD-9 codes showed modest sensitivity for
detecting CAP, leaving at least one quarter of pneumonia
cases undetected [48]. Fourth, statistical heterogeneity was
detected when quantitative pooling was performed. In
addition, small-study effects were detected in this study.
Thus, caution with interpretation of the results is necessary,
and these results should be confirmed by future studies.
Conclusions
This meta-analysis suggests that obese individuals may
be at higher risk for pneumonia, but they might have a
lower mortality risk. Additional prospective studies with
adjustment for more confounding factors are warranted
before a conclusion can be drawn.
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